EI
Emervax develops next‑generation vaccines using its emxRNA circular RNA platform, combining advanced purification and delivery technologies. The pipeline targets emerging viral pathogens and hard‑to‑treat cancers, offering modular vaccine candidates for global health challenges. Revenue is generated through product sales, licensing agreements, and partnerships with pharmaceutical and public‑health organizations.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Emervax develops next‑generation vaccines using its emxRNA circular RNA platform, combining advanced purification and delivery technologies. The pipeline targets emerging viral pathogens and hard‑to‑treat cancers, offering modular vaccine candidates for global health challenges. Revenue is generated through product sales, licensing agreements, and partnerships with pharmaceutical and public‑health organizations.